Abstract
Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Current HIV Research
Title:Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2
Volume: 10 Issue: 4
Author(s): Ruth Serra-Moreno and David T. Evans
Affiliation:
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Abstract: Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Export Options
About this article
Cite this article as:
Serra-Moreno Ruth and T. Evans David, Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792496
DOI https://dx.doi.org/10.2174/157016212800792496 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Current Cancer Drug Targets The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Recent Applications of RNAi in Mammalian Systems
Current Pharmaceutical Biotechnology Taking Cell Culture in Drug Discovery to the Third Dimension - A Patent Review
Recent Patents on Biomedical Engineering (Discontinued) Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Efficacy and Tolerability of Vinorelbine in the Cancer Therapy
Current Drug Safety Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry